New therapies for castration-resistant prostate cancer

New England Journal of Medicine

Volumn 363, Issue 5, 2010, Pages 479-481

  Longo, Dan L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANTINEOPLASTIC AGENT; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MDV3100; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROSTVAC VF; PROVENGE; UNCLASSIFIED DRUG;

BONE SCINTISCANNING; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG COST; EDITORIAL; HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE;

EID: 77955080349     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1006300     Document Type: Editorial

References (14)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
2. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
3. de Souza AP, Bonorino C. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Rev Anticancer Ther 2009;9:1317-32.
4. Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653-9.
5. Yu EY, Gulati R, Telesca D, et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010;28:2668-73.
6. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW. All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010 February 10 (Epub ahead of print).
7. Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010;20:241-6.
8. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
9. Schiavo R, Baatar D, Olkhanud P, et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006;107:4597-605.
10. Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010;13:351-61.
11. Knudsen KE, Penning TM. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010;21:315-24.
12. Di Lorenzo G, Buonerba C, Autorino R, et al. Castration-esistant prostate cancer: current and emerging treatment strategies. Drugs 2010;70:983-1000.
13. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-95.
14. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46.